Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report)‘s stock had its “overweight” rating restated by analysts at Piper Sandler in a research report issued to clients and investors on Monday, Benzinga reports. They currently have a $270.00 price objective on the stock.
PRAX has been the topic of several other research reports. Robert W. Baird started coverage on Praxis Precision Medicines in a research report on Wednesday, May 1st. They issued an “outperform” rating and a $117.00 price objective on the stock. HC Wainwright restated a “buy” rating and issued a $105.00 price objective on shares of Praxis Precision Medicines in a research report on Tuesday, May 14th. Jefferies Financial Group upped their price objective on Praxis Precision Medicines from $75.00 to $128.00 and gave the stock a “buy” rating in a research report on Tuesday, March 26th. Guggenheim began coverage on Praxis Precision Medicines in a research report on Tuesday, June 18th. They issued a “buy” rating and a $155.00 price objective on the stock. Finally, Truist Financial reiterated a “buy” rating and set a $150.00 target price on shares of Praxis Precision Medicines in a research report on Thursday, May 16th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $137.38.
Read Our Latest Research Report on PRAX
Praxis Precision Medicines Price Performance
Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report) last issued its quarterly earnings results on Monday, May 13th. The company reported ($2.84) earnings per share for the quarter, missing the consensus estimate of ($2.01) by ($0.83). Praxis Precision Medicines had a negative return on equity of 101.99% and a negative net margin of 5,711.85%. The business had revenue of $0.43 million during the quarter, compared to analyst estimates of $2.75 million. As a group, analysts forecast that Praxis Precision Medicines will post -10.13 EPS for the current year.
Institutional Trading of Praxis Precision Medicines
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Farallon Capital Management LLC acquired a new stake in shares of Praxis Precision Medicines during the 1st quarter worth about $3,051,000. RA Capital Management L.P. acquired a new position in Praxis Precision Medicines in the 1st quarter valued at about $50,548,000. Janus Henderson Group PLC acquired a new position in Praxis Precision Medicines in the 1st quarter valued at about $18,878,000. Kingdon Capital Management L.L.C. grew its position in Praxis Precision Medicines by 1.0% in the 1st quarter. Kingdon Capital Management L.L.C. now owns 350,000 shares of the company’s stock valued at $21,357,000 after acquiring an additional 3,335 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD acquired a new position in Praxis Precision Medicines in the 1st quarter valued at about $32,707,000. 67.84% of the stock is owned by institutional investors and hedge funds.
About Praxis Precision Medicines
Praxis Precision Medicines, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy.
Featured Articles
- Five stocks we like better than Praxis Precision Medicines
- Stock Splits, Do They Really Impact Investors?
- Applied Digital Boosts Stock with Cutting-Edge AI Data Centers
- What to Know About Investing in Penny Stocks
- Chewy Stock Surges on Roaring Kitty’s Disclosure of Major Stake
- The How and Why of Investing in Gold Stocks
- How to Invest in Gold: A Complete Guide
Receive News & Ratings for Praxis Precision Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Praxis Precision Medicines and related companies with MarketBeat.com's FREE daily email newsletter.